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Introduction: Several inflammatory markers have been associated with a
greater likelihood of cardiovascular diseases. Of those C-reactive protein
(CRP) and myeloperoxidase (MPO) are the most well known.
The development of sensitive rapid tests for MPO and hs-CRP, together
with a simple hand-held reader promises to open up the possibility of identi-
fying high-risk patients early enough for the introduction of prophylactic
therapies or the adoption of beneficial life-style changes.
Objectives: We propose to evaluate the cardiovascular risk for 50 hyper-
tensive and diabetic patients by rapid tests for MPO and hs-CRP and to com-
pare with endothelial function and Framingham score.
Results: We evaluate prospectively 50 patients without cardiovascular
events, the mean age is 53 years, 78% have mean or high CV risk according
to the Framingham score and 38% presenting endothelial dysfunction.
The statistical analysis showed a significant association between the rate of
hs-CRP, the Framingham score (p=0,02, r=0,424), with the metabolic syn-
drome (p=0,0001), and endothelial dysfunction (p=0,001).
MPO level is correlated with the sex (p=0,002), age (p=0,05), as well with
the Framingham score (r=0,345), the metabolic syndrome (p=0,001), the
endothelial dysfunction (p=0,001), and also with the LDL cholesterol.
(p=0,04; r=0,3).
In the same way, a significant Correlation was shown between hs-CRP and
MPO (p=0,016; r=0,34).
The hs-CRP test showed a good specificity (85%), and VPP (96%), a weak
VPN (27%).
However MPO test showed a low specificity (25%) low sensitivity (25%),
VPP of (73%) and a low VPN (5%).
Conclusion: The hs-CRP represents the inflammatory marker most rele-
vant in the prediction of risk CV, better than the MPO.
These markers reflect the clinical potential of atherothrombotic disease
may allow more precise risk stratification and prognostication in high-risk
populations, and perhaps earlier diagnosis and intervention in patients at risk
for or with occult cardiovascular disease.
